Insight

Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer

Elisa Agostinetto/X

Jan 5, 2025, 18:21

Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer

Elisa Agostinetto, Medical Research Fellow at the University Hospital of Brussels, shared a post on LinkedIn:

“What is the impact of drug-drug interactions between palbociclib and proton pump inhibitors (PPI) in breast cancer?

Can PPI use explain why the PALLAS trial was negative?

Now out in ESMO our analysis of PALLAS exploring this question.”

Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)

Authors: E. Agostinetto, G. Pfeiler, D. Hlauschek, E.L. Mayer, M. Lambertini, E. de Azambuja, M. Bellet-Ezquerra, J.L. Meisel, G. Rubovszky, N. Zdenkowski, Y. Novik, M. Ruiz-Borrego, K.A. Gelmon, E.P. Mamounas, H. Iwata, D.R. Lu, L. Soelkner, C. Fesl, M. Gnant, A. DeMichele

Elisa Agostinetto: Drug-drug interactions between palbociclib and PPI in breast cancer

A DeMichele Breast Cancer C. Fesl cancer D. Hlauschek D.R. Lu E. Agostinetto E. de Azambuja E.L. Mayer E.P. Mamounas Elisa Agostinetto G. Pfeiler G. Rubovszky H. Iwata J.L. Meisel K.A. Gelmon L. Soelkner M. Bellet-Ezquerra M. Gnant M. Lambertini M. Ruiz-Borrego N. Zdenkowski OncoDaily Oncology palbociclib PALLAS trial Y. Novik

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer

Daiichi Sankyo's and Astrazeneca's press release on ENHERTU®: Latest Updates from DESTINY-Gastric04 trial

13-year-old Cancer Survivor Sworn in as a Secret Service agent by President Trump - The White House

The European Parliament Intergroup on Cancer and Rare Diseases has been set in motion - ECO